Sun upbeat on CML molecule that hits T315L mutations
This article was originally published in Scrip
Sun Pharma Advanced Research Company (SPARC) has outlined details of its emerging NCE pipeline and novel drug delivery system (NDDS) R&D programmes, including an early stage tyrosine kinase inhibitor for chronic myeloid leukaemia (SUN-K706), which inhibits T315I, a key gene mutation that arises during treatment with existing CML marketed drugs.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.